Opportunity Information: Apply for CDC RFA PS13 1307
Apply for CDC RFA PS13 1307
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Perinatal Hepatitis B Prevention Program, Supplemental Evaluation Projects (PHBPP SEP)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270 Adult Viral Hepatitis Prevention and Control.
- This funding opportunity was created on Nov 1, 2012 and posted on Sep 17, 2012.
- Applicants must submit their applications by Nov 8, 2012 GMO has extended the Application Due Date to reflect November 5, 2012.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,200,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Applicants Eligible applicants that can apply for this funding opportunity are listed below The following entities are eligible to apply The current 64 grantees with established Perinatal Hepatitis B Prevention Programs (PHBPP), which include the 50 state health departments or their bona fide agent and the District of Columbia, the cities of New York, Philadelphia, Houston, Chicago, San Antonio, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, and Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. Competition is limited to the entities listed above because they have the primary responsibility for carrying out the public health assurance functions required to achieve the desired outcomes and performance goals established by CDC. A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov. Limited competition for this RFA is justified based on the following This FOA is limited to State or local health department jurisdictions with established Perinatal Hepatitis B Prevention Programs (PHBPP). The PHBPP have the necessary infrastructure in place to perform the activities required, and have the experience needed to successfully complete the required objectives. PHBPP have the primary responsibility for carrying out the public health assurance functions required to achieve the desired outcomes and progress toward elimination of mother to children hepatitis B transmission which is a national goal of HHS, CDC, ACIP, and Healthy People 2020. PHBPP have been funded by CDC since 1990 through immunization Program grants to 64 jurisdictions in the United States, cities, territories, and freely associated island nations Key program requirements of the PHBPP programs are to identify all hepatitis B infected pregnant women and case manage their infants for timely receipt and completion of post exposure interventions to prevent mother to child hepatitis B transmission. Despite active efforts, in 2008 (last data available) PHBPPs identified approximately 50 of the expected number of births to hepatitis B infected pregnant women. Although hepatitis B birth dose provides a safety net for infants who are not identified for coverage in the United States, coverage was only 64 in 2010. Core PHBPP will continue to be supported by CDC from 2013 2017 through an immunization funding opportunity announcement # CDC RFA IP13 1301, Immunization and Vaccines for Children Program .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Perinatal Hepatitis B Prevention Program, Supplemental Evaluation Projects (PHBPP SEP) is a CDC discretionary funding opportunity offered as a cooperative agreement (Funding Opportunity Number CDC RFA PS13-1307; CFDA 93.270, Adult Viral Hepatitis Prevention and Control). Its central aim is to advance the HHS Viral Hepatitis Action Plan by strengthening and evaluating public health work that prevents hepatitis B virus (HBV) transmission from mother to child. The opportunity is built around three practical, high-impact priorities: eliminating perinatal (mother-to-infant) HBV transmission, making sure pregnant people who are infected with HBV receive timely clinical evaluation and care (including attention to those with high viral load, where improved maternal management can further reduce infant infection risk), and ensuring that every hospital or birthing center reliably administers a hepatitis B vaccine birth dose to all newborns before discharge, which functions as a critical safety net when maternal HBV infection is not identified in time.
This supplemental funding was designed for jurisdictions that already operate established Perinatal Hepatitis B Prevention Programs (PHBPP) and therefore already have the staff, systems, and relationships needed to carry out the specialized work of identifying HBV-infected pregnant women and case managing their infants to ensure post-exposure prophylaxis and completion of recommended interventions. The announcement highlights ongoing performance gaps that motivate the supplemental evaluation emphasis, noting that PHBPPs identified only about half of the expected births to HBV-infected pregnant women in 2008 (the most recent data cited) and that national hepatitis B birth dose coverage was 64 percent in 2010. In other words, even with longstanding programs in place, too many exposed infants can be missed unless identification systems improve and universal birth dose practices are consistently implemented across birthing facilities.
Eligibility is limited competition and restricted to the 64 current PHBPP grantees. These include the 50 state health departments (or their bona fide agents) and the District of Columbia, plus specified large cities (New York, Philadelphia, Houston, Chicago, San Antonio), U.S. territories and freely associated jurisdictions (Puerto Rico, U.S. Virgin Islands, Commonwealth of the Northern Mariana Islands, American Samoa, Guam), and the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. If applying as a bona fide agent in place of a state or local government, the applicant must provide a legal, binding agreement documenting that status, submitted as an attachment through Grants.gov. The CDC justifies this limitation by emphasizing that these jurisdictions already hold primary public health assurance responsibility for perinatal HBV prevention, have established infrastructure and experience, and are positioned to deliver measurable progress toward national goals, including those reflected in HHS priorities, CDC guidance, ACIP recommendations, and Healthy People 2020 objectives. The PHBPP effort itself has been funded by CDC since 1990, underscoring that this supplemental announcement is meant to build on mature programs rather than start new ones.
Funding details in the announcement indicate an estimated total program funding level of $1.2 million, with an expected four awards. Individual awards are anticipated to fall between a floor of $70,000 and a ceiling of $200,000, and there is no cost sharing or matching requirement. The opportunity was posted September 17, 2012, with an original closing date of November 2, 2012; the closing date was subsequently extended, with the current closing date listed as November 8, 2012 (and text indicating the GMO extended the due date to reflect November 5, 2012). The archive date is December 2, 2012. The funding instrument being a cooperative agreement signals that CDC anticipated substantial federal involvement, typically meaning awardees would coordinate closely with CDC on project design, implementation, and evaluation expectations.
The program narrative also clarifies that these awards are supplemental evaluation projects, not a replacement for core PHBPP operations. Core PHBPP activities were expected to continue under a separate immunization funding mechanism for 2013-2017 (CDC RFA IP13-1301, Immunization and Vaccines for Children Program). In practice, this means the supplemental awards were intended to help jurisdictions test, assess, and strengthen strategies that close known gaps, such as improving identification of HBV-infected pregnant women, ensuring timely linkage of infected pregnant women to appropriate evaluation and care, and driving more consistent adoption of universal hepatitis B birth dose policies and procedures in hospitals and birthing centers.
For assistance accessing the full announcement, the listed contact is the CDC Procurement and Grants Office (PGO) at 770-488-2700 or pgotim@cdc.gov.
FAQs: Perinatal Hepatitis B Prevention Program, Supplemental Evaluation Projects (PHBPP SEP)
What is the PHBPP Supplemental Evaluation Projects (PHBPP SEP) funding opportunity?
PHBPP SEP is a CDC discretionary funding opportunity offered as a cooperative agreement to support supplemental evaluation projects within established Perinatal Hepatitis B Prevention Programs (PHBPP). The Funding Opportunity Number is CDC RFA PS13-1307, and the CFDA listing referenced is 93.270 (Adult Viral Hepatitis Prevention and Control).
What is the main goal of this opportunity?
The central aim is to advance the HHS Viral Hepatitis Action Plan by strengthening and evaluating public health work that prevents hepatitis B virus (HBV) transmission from mother to child (perinatal transmission).
What are the key priorities emphasized in the announcement?
The opportunity is organized around three practical priorities: (1) eliminating perinatal HBV transmission, (2) ensuring pregnant people infected with HBV receive timely clinical evaluation and care (including attention to those with high viral load), and (3) ensuring hospitals and birthing centers reliably administer a hepatitis B vaccine birth dose to all newborns before discharge.
Why is the hepatitis B vaccine birth dose highlighted as a priority?
The birth dose is described as a critical safety net, particularly when maternal HBV infection is not identified in time. Consistent administration before discharge helps reduce the risk of missed prevention opportunities for exposed infants.
Who is eligible to apply?
Eligibility is limited competition and restricted to the 64 current PHBPP grantees. The eligible set includes the 50 state health departments (or their bona fide agents) and the District of Columbia, plus specified large cities and designated U.S. territories and freely associated jurisdictions listed in the announcement.
Which large cities are specifically included as eligible jurisdictions?
The announcement specifies the following large cities: New York, Philadelphia, Houston, Chicago, and San Antonio.
Which territories and freely associated jurisdictions are included?
The announcement lists Puerto Rico, the U.S. Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, and Guam. It also includes the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Can a jurisdiction apply through a bona fide agent?
Yes. If applying as a bona fide agent in place of a state or local government, the applicant must provide a legal, binding agreement documenting that status.
What documentation is required for bona fide agent status?
A legal, binding agreement that documents bona fide agent status is required, and it must be submitted as an attachment through Grants.gov.
Why is eligibility limited to current PHBPP grantees?
CDC justifies the limitation by noting that these jurisdictions already hold primary public health assurance responsibility for perinatal HBV prevention, have established infrastructure and experience, and are positioned to deliver measurable progress toward national goals and related priorities (including CDC guidance, ACIP recommendations, and Healthy People 2020 objectives).
Is this funding intended to start new perinatal hepatitis B programs?
No. The announcement frames these awards as supplemental evaluation projects designed for jurisdictions that already operate established PHBPPs with existing staff, systems, and relationships.
How long has CDC funded the PHBPP effort?
The PHBPP effort has been funded by CDC since 1990, and the supplemental announcement is intended to build on mature programs rather than create new ones.
What types of gaps or challenges does this supplemental funding aim to address?
The announcement points to performance gaps such as incomplete identification of births to HBV-infected pregnant women and suboptimal hepatitis B birth dose coverage, motivating a focus on evaluation and strengthened strategies to close these gaps.
What performance gaps are cited in the announcement?
Two specific data points are cited: PHBPPs identified only about half of the expected births to HBV-infected pregnant women in 2008 (the most recent data cited), and national hepatitis B birth dose coverage was 64 percent in 2010.
What is meant by “supplemental evaluation projects” in this context?
The awards are described as supplemental projects that help jurisdictions test, assess, and strengthen strategies to improve outcomes (such as identification, linkage to care, and universal birth dose implementation). They are not described as a replacement for core PHBPP operations.
Are these awards intended to replace core PHBPP operations funding?
No. The narrative clarifies that the awards are supplemental and not a replacement for core PHBPP operations, which were expected to continue under a separate immunization funding mechanism for 2013-2017 (CDC RFA IP13-1301, Immunization and Vaccines for Children Program).
What is the total estimated funding amount and how many awards are expected?
The announcement estimates a total program funding level of $1.2 million, with an expected four awards.
What is the anticipated award size per recipient?
Individual awards are anticipated to range from $70,000 (floor) to $200,000 (ceiling).
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
What funding instrument is being used and what does that imply?
The funding instrument is a cooperative agreement. The announcement notes this signals anticipated substantial federal involvement, typically meaning awardees would coordinate closely with CDC on project design, implementation, and evaluation expectations.
When was the opportunity posted and what are the key dates mentioned?
The opportunity was posted September 17, 2012. The original closing date was November 2, 2012, and it was extended. The current closing date is listed as November 8, 2012, while the text also indicates the GMO extended the due date to reflect November 5, 2012. The archive date is December 2, 2012.
Why are there multiple closing date references (November 5 vs. November 8)?
The information provided includes two references: a “current closing date” listed as November 8, 2012, and separate text indicating the Grants Management Officer (GMO) extended the due date to reflect November 5, 2012. Applicants would need to reconcile these dates using the official posting and instructions referenced in the announcement.
What is the relationship between this opportunity and national plans or recommendations?
The announcement ties the work to advancing the HHS Viral Hepatitis Action Plan and references alignment with HHS priorities, CDC guidance, ACIP recommendations, and Healthy People 2020 objectives.
What is the focus regarding pregnant people infected with HBV?
The priorities include ensuring pregnant people infected with HBV receive timely clinical evaluation and care, including attention to those with high viral load where improved maternal management can further reduce infant infection risk.
What is the focus regarding hospitals and birthing centers?
A stated priority is ensuring every hospital or birthing center reliably administers a hepatitis B vaccine birth dose to all newborns before discharge, supporting universal and consistent birth dose policies and procedures.
How can someone get help accessing the full announcement?
The listed contact for assistance is the CDC Procurement and Grants Office (PGO) at 770-488-2700 or by email at pgotim@cdc.gov.
What is the Funding Opportunity Number and CFDA number for this announcement?
The Funding Opportunity Number is CDC RFA PS13-1307. The CFDA number referenced is 93.270 (Adult Viral Hepatitis Prevention and Control).
Browse more opportunities from the same category: Health
Next opportunity: TECHNICAL ASSISTANCE TO BROWNFIELDS COMMUNITIES
Previous opportunity: FY13 Great Lakes Bay Watershed Education and Training Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS13 1307
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS13 1307) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV Early Intervention Services (EIS) Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 13 252 Funding Number: HRSA 13 252 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Media Project (HMP), Kenya Apply for RFA 615 12 000006 Funding Number: RFA 615 12 000006 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $8,000,000 |
| Immunity in the Elderly (R01) Apply for RFA AI 12 038 Funding Number: RFA AI 12 038 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Ancillary Studies in Clinical Trials (R01) Apply for RFA HL 14 004 Funding Number: RFA HL 14 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21) Apply for PA 12 292 Funding Number: PA 12 292 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01) Apply for PA 12 291 Funding Number: PA 12 291 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Care Grant Program Part B Apply for HRSA 13 158 Funding Number: HRSA 13 158 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NHLBI Clinical Trial Pilot Studies (R34) Apply for PAR 13 002 Funding Number: PAR 13 002 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Functional Assays to Screen Genomic Hits (R21/R33) Apply for RFA HL 13 027 Funding Number: RFA HL 13 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 13 011 Funding Number: RFA AG 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Patient Oriented Research Career Development Award in Aging (K23) Apply for RFA AG 13 012 Funding Number: RFA AG 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenetic Inheritance and Transgenerational Effects of Alcohol (R01) Apply for PA 13 003 Funding Number: PA 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenetic Inheritance and Transgenerational Effects of Alcohol (R21) Apply for PA 13 004 Funding Number: PA 13 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Limited Competition Continuation of the National Institute on Aging Multicenter Clinical Trial The LIFE Study (U01) Apply for PAR 13 001 Funding Number: PAR 13 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| TECHNICAL ASSISTANCE AND SUPPORT OF HIV PREVENTION, CARE TREATMENT PROGRAMS AND OTHER INFECTIOUS DISEASES THAT IMPACT HIV INFECTED PATIENTS IN SUPPORT OF THE PRESIDENTS EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS09 9040401SUPP13 Funding Number: CDC RFA PS09 9040401SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $635,768 |
| Presidents Malaria Initiative Apply for USAID GUINEA RFA 675 13 000001 Funding Number: USAID GUINEA RFA 675 13 000001 Agency: Senegal USAID Dakar Category: Health Funding Amount: $18,428,129 |
| Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01) Apply for RFA AG 13 013 Funding Number: RFA AG 13 013 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alzheimers Disease Prevention Trials (R01) Apply for RFA AG 13 015 Funding Number: RFA AG 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $4,500,000 |
| Alzheimers Disease Phase I Clinical Trials (R01) Apply for RFA AG 13 016 Funding Number: RFA AG 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 13 008 Funding Number: PAR 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS13 1307", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.